Janux Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Janux Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($24.31M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($33.86M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($23.51M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($28.06M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.96M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($14.76M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.57M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($17.51M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($17.46M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.70M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.89M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.41M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($10.77M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($6.21M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($2.28M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($1.26M) | Nov 9, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.46M) | Aug 10, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($35.25M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($45.12M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($34.90M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($35.84M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($13.82M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($20.16M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($15.81M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.75M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($20.28M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($18.02M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($17.26M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.54M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($10.90M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($6.25M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($2.28M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($1.26M) | Nov 9, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($1.11M) | Aug 10, 2021 |